{"filing":{"accession_number":"0001628280-26-059952","cik":"0002007191","ticker":"TLPPF","company_name":"Telix Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-02","primary_document":"telix-6kphase3bipassenroll.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026059952/telix-6kphase3bipassenroll.htm"},"events":[{"id":31115,"run_id":28538,"accession_number":"0001628280-26-059952","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Telix announced completion of enrollment in the Phase 3 BiPASS study (350 patients) and alignment with the FDA on an NDA pathway for its PSMA-PET imaging agents (Illuccix and Gozellix). This is a material clinical and regulatory milestone—successful completion of a pivotal registrational trial and FDA pathway alignment—that advances the company's product pipeline and could expand market access. The event is operational/strategic (clinical trial progress and regulatory engagement) rather than a discrete financial, governance, or legal event, and does not fit the earnings_release, ma_activity, or other specific categories.","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":[{"id":33916,"accession_number":"0001628280-26-059952","item_number":"EX-99.1","item_title":"a20260902bipasscompletio.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Telix announced completion of enrollment in the Phase 3 BiPASS study (350 patients) and alignment with the FDA on an NDA pathway for its PSMA-PET imaging agents (Illuccix and Gozellix). This is a material clinical and regulatory milestone—successful completion of a pivotal registrational trial and FDA pathway alignment—that advances the company's product pipeline and could expand market access. The event is operational/strategic (clinical trial progress and regulatory engagement) rather than a discrete financial, governance, or legal event, and does not fit the earnings_release, ma_activity, or other specific categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:06:19.132286+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33916,"accession_number":"0001628280-26-059952","item_number":"EX-99.1","item_title":"a20260902bipasscompletio.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Telix announced completion of enrollment in the Phase 3 BiPASS study (350 patients) and alignment with the FDA on an NDA pathway for its PSMA-PET imaging agents (Illuccix and Gozellix). This is a material clinical and regulatory milestone—successful completion of a pivotal registrational trial and FDA pathway alignment—that advances the company's product pipeline and could expand market access. The event is operational/strategic (clinical trial progress and regulatory engagement) rather than a discrete financial, governance, or legal event, and does not fit the earnings_release, ma_activity, or other specific categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:06:19.132286+00:00","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-09-01"}]}